LASN 03
Alternative Names: LASN-03Latest Information Update: 17 Jul 2023
At a glance
- Originator Lassen Therapeutics
- Class Anti-inflammatories; Antibodies; Antifibrotics; Antineoplastics; Immunotherapies
- Mechanism of Action Interleukin 11 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cancer; Fibrosis
Most Recent Events
- 13 Jul 2023 Discontinued for Cancer in USA (Parenteral) (Lassen Therapeutics pipeline, July 2023)
- 13 Jul 2023 Discontinued for Fibrosis in USA (Parenteral) (Lassen Therapeutics pipeline, July 2023)
- 25 Apr 2023 LASN 03 is available for licensing as of 25 Apr 2023. https://lassentherapeutics.com/about/our-approach/ (Lassen Therapeutics website, April 2023)